Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. - Wikidata - wikimedia - TriplyDB

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

http://www.wikidata.org/entity/Q30354637

about

Clinical features and treatment strategy for HPV-related oropharyngeal cancer.The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.Worldwide burden of cancer attributable to HPV by site, country and HPV type.Human papillomavirus (HPV): making the case for 'Immunisation for All'.Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.Cancer incidence in Germany attributable to human papillomavirus in 2013.A systematic review of factors influencing human papillomavirus vaccination among immigrant parents in the United States.Strengthening the case for gender-neutral and the nonavalent HPV vaccine.HPV genotypes detected by linear array and next-generation sequencing in anal samples from HIV positive men who have sex with men in Mexico.Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.Survival of human papillomavirus-associated cancers: Filling in the gaps.Human Papillomavirus Type 16 Integration Analysis by Real-time PCR Assay in Associated Cancers.Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention.Human Papillomavirus Vaccination: Making Sense of the Public Controversy

P2860

Q30249150-A8D008C4-034E-4CE0-9FC9-EEDC1D1C3A6B Q30251408-46634F11-DB36-4CDC-899A-7FCB67B33550 Q36745242-F9DC3E08-C41E-4890-9180-50CAA9A642D5 Q38859779-74D33E82-A24E-4BCF-A2F3-6D5F41FD2E76 Q38919213-C70FD9A3-4D7E-4BB7-A204-FFE2AB683A45 Q40252793-7139ACB1-073C-4155-844C-D4059195190A Q42690795-86719026-75AD-4753-943A-276F0907689D Q47210727-53D4B8DB-BC2A-4A04-976A-44188EA18918 Q47554428-659065B3-4B54-4626-B267-A41092218205 Q47565939-522B2F08-EBA4-427B-B632-BFED8CB872F7 Q47572082-10EB780E-A317-4538-B2F0-B9526C3AF4AB Q48361315-30520B21-550B-4842-8AAF-5AAADB33BEBC Q53177082-CC6EA600-9C21-4969-9EA5-88B78B4CAD24 Q55385410-ED0F54C3-59BD-42E9-A9A6-C3D2C53E9799 Q57089326-3461F7D6-5757-4E08-86DA-CC04D1497130

P2860

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

http://www.wikidata.org/entity/Q30354637

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@ast

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@en

type

label

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@ast

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@en

prefLabel

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@ast

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@en

P1433

Q30354637-02520FD7-C2F5-410A-8B30-51009007CE95

P1476

Q30354637-9D952EF1-D5E8-46BC-9081-31543507B495

P2093

Q30354637-0622D39A-638D-41AC-B38B-A3092293BC55

Q30354637-0AD4A631-AC72-4FA9-B4D5-2F58D652C977

Q30354637-2D29DE6F-DC02-453B-AB70-E950F6CCD52D

Q30354637-30ECC315-1855-4F13-9737-4B062B8F8481

Q30354637-35524110-A380-496D-A4C3-A50E327B3CCA

Q30354637-4A0BBED6-D1C8-43A1-978C-19E014E28742

Q30354637-54305D52-C666-49EB-B756-63498219B663

Q30354637-6D615F89-B894-42DD-8A83-2EECBCBCF1E9

Q30354637-C1A4632E-46F1-4DB2-BC82-0C0CCE3D9157

Q30354637-E16E2675-1A6A-4776-B5C2-ED8432D13572

P2860

Q30354637-0496CA52-E828-4999-97DF-E9A7A82856AA

Q30354637-0DEE2B68-4E22-416D-9770-3F0CFED82669

Q30354637-12AE62C0-06B5-460D-AE71-A5731B204321

Q30354637-290D94DD-ACF1-482C-9669-8EB720F9FDF7

Q30354637-2B8A4315-5A5D-41F7-AC40-B2E8606B648E

Q30354637-2BFF2C54-59E1-4922-A095-2608245AE142

Q30354637-2DBA810D-6980-48F0-B550-9FF586924D61

Q30354637-2E12DCA1-8DE5-4151-A3CF-53EFE495858C

Q30354637-32260B28-AA5D-483A-A478-BA71C59FD4B0

Q30354637-41C10104-817D-495B-AE6B-134AA10FE6CA

P31

Q30354637-8CF09724-3FF5-4FE2-9948-5FC16239F816

P356

Q30354637-CA5A9144-9F2C-42B1-B348-C182E68878F1

P407

Q30354637-0BD45B94-46BA-458B-B411-8C5AF46397AA

P433

Q30354637-FEC19B5A-1321-4F46-8BBB-9B7BCC53D37E

P478

Q30354637-17842987-6AF5-490D-B9F5-8E2525CA1880

P50

Q30354637-05538E46-7192-44C5-A0DE-8D42D42377EB

Q30354637-0D27F450-3452-4D1F-A6FA-A54553F1594D

Q30354637-0DB39B2F-5693-433E-AA63-F7957EBFB4AA

Q30354637-59395D8B-7161-4BD5-A644-D271AAC6F347

Q30354637-D3729EF6-BF44-4673-ADCE-4D9E0AEC5A38

Q30354637-DF64A9EB-84EA-4462-A1E4-346934751FBC

P577

Q30354637-C25D55A7-24B4-428F-98DB-CE5B1970BC87

P698

Q30354637-229A3BFD-5EB2-4823-BC32-F6566EE06391

P932

Q30354637-2ED8376A-1EA4-4B17-A153-BB7AC45C2AA0

P356

P1433

Journal of the National Cancer Institute

P1476

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

@en

P2093

Aimée R Kreimer

http://www.w3.org/2001/XMLSchema#string

Carolina Porras

http://www.w3.org/2001/XMLSchema#string

Costa Rica HPV Vaccine Trial (CVT) Group

http://www.w3.org/2001/XMLSchema#string

Daniel C Beachler

http://www.w3.org/2001/XMLSchema#string

Douglas R Lowy

http://www.w3.org/2001/XMLSchema#string

John Schussler

http://www.w3.org/2001/XMLSchema#string

John T Schiller

http://www.w3.org/2001/XMLSchema#string

Paula Gonzalez

http://www.w3.org/2001/XMLSchema#string

Rolando Herrero

http://www.w3.org/2001/XMLSchema#string

Silvia Jimenez

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels

Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus.

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus

Models for longitudinal data: a generalized estimating equation approach.

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Anal human papillomavirus infection in women and its relationship with cervical infection

P31

scholarly article

P356

10.1093/JNCI/DJV302

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Sholom Wacholder

Allan Hildesheim

Ana Cecilia Rodríguez

Mahboobeh Safaeian

P577

2015-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26467666

http://www.w3.org/2001/XMLSchema#string

P932

4862406

http://www.w3.org/2001/XMLSchema#string